The AOP of the July Nature Medicine contains the article “Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome” by Kuo et al from Georgetown U. I’ve only read the abstract and stories so far (like this one from the Scientist and the press release from GU), but it’s [...]
As you’ll read in Therapeutics Daily and elsewhere, Novartis reported the delay of FDA’s review of Galvus, its answer to Merck’s recently approved Januvia, by three months. Novartis said it submitted additional clinical data, triggering the FDA to add time to its review-cycle clock.
What interests me about the story is the reasoning behind Novartis’ move. Apparently, [...]
I’ll add this one into my vast collection of “I had no idea” new items. As someone who performed experiments, and worked closely with many other scientists who performed many experiments, on rodents fed commercial rodent chow, I have to say that I don’t recall a single discussion about the contents of the chow, outside [...]
Another twist to the tragic story of the Tegenero CD28 agonist Phase 1 trial in which six healthy volunteers were strciken with severe adverse reactions that will leave them recovering for months. In this Times piece, Professor Angus Dagleish questions the decision to allow the trial, given prior experience with another monoclonal antibody that, like [...]
